DGX · Quest Diagnostics Inc
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Organic requisition volume | 13% | Q2 2026 | — |
|
|
|||
| Requisition volume | 13.1% | Q2 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DGX
this stock
Quest Diagnostics Inc
|
$26.46B | +39.3% | +11.8% | 25.5 | 3.3% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.80B | +5.9% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -7.6% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$45.29B | +41.9% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -16.9% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DGX | +1.7% | +15.2% | +14.5% | +3.8% | +39.3% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +2.1% | +12.3% | +3.0% | +0.8% | +26.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.